CorVel Corporation (CRVL) — Form 10-Q Summary
Business context and reporting period
CorVel provides managed-care and medical-cost-containment services, principally for workers’ compensation, auto insurance, and group health claims. It reports one operating segment. The supplied filing is for the quarter ended December 31, 2022 (fiscal 2023 third quarter), not 2021 Q3 as indicated in the request. Financial comparisons are against the three and nine months ended December 31, 2021. Figures below are in U.S. dollars.
Financial performance and liquidity
- Quarter: Revenue was $179.4 million, up 9.0%; gross profit was $40.3 million, up 14.7%; and net income was $16.8 million, up 21.6%. Diluted EPS was $0.96 versus $0.76.
- Quarterly gross margin was 22.5% versus 21.4%; pretax margin was 12.4% versus 10.7%. G&A was $18.1 million, up 3.6%; the effective tax rate rose to 24.2% from 21.6%.
- Nine months: Revenue was $533.1 million, up 12.3%; gross profit was $116.3 million, up 6.6%; net income was $48.2 million, up 3.0%; diluted EPS was $2.73 versus $2.57. Gross margin declined to 21.8% from 23.0%; pretax margin declined to 11.6% from 12.3%.
- Quarterly revenue growth reflected patient management services (+10.4%) and network solutions (+6.5%). For the nine months, those service lines grew 12.9% and 11.0%, respectively.
- Cash flow, nine months: Operating cash flow was $69.5 million versus $50.4 million. Investing outflow was $19.2 million, primarily capital expenditures; financing outflow was $69.8 million, primarily share repurchases.
- Cash and cash equivalents were $78.0 million at December 31, 2022, down from $97.5 million at March 31, 2022. Working capital was $70.3 million, down from $93.6 million. The company reported no debt outstanding. Current assets were $256.7 million and current liabilities $186.4 million.
- Stock repurchases totaled $75.1 million for the nine months. In November 2022, the board expanded the program authorization by 1 million shares to 39 million shares over its life.
Material changes, outlook, and risks
- Management attributed revenue growth primarily to higher TPA and related patient-management revenue and increased bill-review activity. New claims rose 7% in the quarter and 15% for the nine-month period versus the respective prior-year periods.
- Cost of revenue rose 7.5% in the quarter and 13.9% for nine months. Management cited higher business volumes, field headcount growth, and wage inflation; nine-month field salaries increased 16.2%.
- Cash from operations improved partly because of the timing of tax payments, including a $7.5 million favorable year-over-year swing. Cash declined principally due to increased share repurchases.
- Management stated that cash and expected operating cash flow should meet requirements for at least the next 12 months and beyond, including planned repurchases. It may reduce or suspend repurchases if earnings or cash flows weaken. No specific revenue or earnings guidance was provided.
- Management noted inflationary pressure on labor, benefits, and leases and warned it could materially affect future pricing and operating expenses. It also cited risks from competition, claim-volume trends, customer renewals and outsourcing decisions, staffing, technology, cybersecurity, regulation, litigation, and COVID-19-related disruption.
- The company reassessed certain lease-renewal assumptions following increased permanent work-from-home expectations, reducing lease assets and liabilities with an immaterial income-statement impact. It reported ordinary-course litigation and believes any resulting payments would not be material.
Important facts for investors to verify
- Confirm the intended reporting period: this filing covers the quarter ended December 31, 2022, despite the request’s “2021 Q3” label.
- Assess whether revenue growth can continue while nine-month gross and pretax margins remain below prior-year levels, particularly amid wage inflation and higher staffing.
- Review the sustainability of operating cash flow, including the effect of tax-payment timing, and the liquidity impact of continued share repurchases.
- Monitor patient-management and network-solutions growth, claim volumes, customer retention, and the conversion of deferred revenue and remaining performance obligations.
- Consider the stated operational, cybersecurity, regulatory, litigation, and inflation risks; management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.